Profit Or Loss [Abstract]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	20 121 EUR	—	—	—	—	—	—	—	61 641 EUR	—	—	—	—	—	—
Profit (loss) from operating activities	—	51 575 EUR	—	—	—	—	—	—	—	12 669 EUR	—	—	—	—	—	—
Finance income	—	6 079 EUR	—	—	—	—	—	—	—	6 934 EUR	—	—	—	—	—	—
Finance costs	—	3 975 EUR	—	—	—	—	—	—	—	1 835 EUR	—	—	—	—	—	—
Profit (loss) before tax	—	49 471 EUR	—	—	—	—	—	—	—	7 570 EUR	—	—	—	—	—	—
Tax expense (income)	—	— EUR	—	—	—	—	—	—	—	— EUR	—	—	—	—	—	—
Profit (loss) from continuing operations	—	49 471 EUR	—	—	—	—	—	—	—	7 570 EUR	—	—	—	—	—	—
Profit (loss)	— EUR	49 471 EUR	— EUR	49 471 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	7 570 EUR	7 570 EUR	— EUR	— EUR	— EUR	— EUR	— EUR
Earnings per share [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations	—	61.00	—	—	—	—	—	—	—	9.00	—	—	—	—	—	—
Basic earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic earnings (loss) per share	—	61.00	—	—	—	—	—	—	—	9.00	—	—	—	—	—	—
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations	—	61.00	—	—	—	—	—	—	—	9.00	—	—	—	—	—	—
Diluted earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diluted earnings (loss) per share	—	61.00	—	—	—	—	—	—	—	9.00	—	—	—	—	—	—